<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005900</article-id><article-id pub-id-type="pmc">PMC11861804</article-id><article-id pub-id-type="doi">10.3390/vetsci12020140</article-id><article-id pub-id-type="publisher-id">vetsci-12-00140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the Immunogenicity of a Pool of Recombinant <italic toggle="yes">Lactococcus lactis</italic> Expressing Eight Antigens of African Swine Fever Virus in a Mouse Model</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-1384-0257</contrib-id><name><surname>Huang</surname><given-names>Jingshan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00140" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Tianqi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Zhanhao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Dailang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mingzhi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4880-5687</contrib-id><name><surname>Qiu</surname><given-names>Hua-Ji</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yongfeng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Hongxia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref><xref rid="c1-vetsci-12-00140" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Yuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00140" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00140" ref-type="aff">2</xref><xref rid="c1-vetsci-12-00140" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Li</surname><given-names>Wentao</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Lang</surname><given-names>Yifei</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00140"><label>1</label>State Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-Reference Laboratory, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China; <email>hjs45333@163.com</email> (J.H.); <email>19990736668@163.com</email> (T.G.); <email>luzhanhao106@163.com</email> (Z.L.); <email>hsrzlxcrb2021zdl@163.com</email> (D.Z.); <email>lmz824925@163.com</email> (M.L.); <email>qiuhuaji@caas.cn</email> (H.-J.Q.); <email>liyongfeng@caas.cn</email> (Y.L.)</aff><aff id="af2-vetsci-12-00140"><label>2</label>College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun 130118, China</aff><author-notes><corresp id="c1-vetsci-12-00140"><label>*</label>Correspondence: <email>wuhongxia@caas.cn</email> (H.W.); <email>sunyuan@caas.cn</email> (Y.S.); Tel.: +86-451-51051708 (Y.S.)</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>140</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>30</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>In light of the urgent need to combat the global threat posed by African swine fever (ASF) to the pig industry, this study generated a pool of recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing eight distinct proteins of African swine fever virus (ASFV), the causative agent of ASF, and evaluated its immunogenicity in mice via both oral gavage and intramuscular injection. The results demonstrate that intramuscular immunization induced high levels of serum IgG antibodies in the mice, while oral immunization resulted in a transient increase in secretory IgA (sIgA) antibodies in mouse feces.</p></abstract><abstract><title>Abstract</title><p>African swine fever (ASF), caused by African swine fever virus (ASFV), poses a great threat to the global pig industry. There is an urgent demand for effective and safe vaccines to address this threat. This study reports the generation and evaluation of a recombinant <italic toggle="yes">Lactococcus lactis</italic> pool, each strain expressing one of eight ASFV antigens (F317L, H171R, D117L, E120R, B602L, CD2v, p54, and p72). We evaluated the immune responses in mice through oral gavage and intramuscular immunization to the recombinant <italic toggle="yes">L. lactis</italic> pool. The results show that the mice immunized via intramuscular injection induced high-level serum IgG antibodies within 7 d post-primary immunization, which was maintained over an extended period. Additionally, there was a marked increase in the interferon gamma (IFN-<italic toggle="yes">&#x003b3;</italic>) and interleukin 10 (IL-10) levels in the sera. In contrast, the mice immunized via oral gavage did not induce obvious serum IgG antibodies. However, they experienced a transient peak of secretory IgA (sIgA) antibodies in fecal samples within 7 d post-primary immunization, which subsequently decreased to levels that were statistically similar to those in the control group. In addition, this study also found that the multi-antigen cocktail vaccination was safe for mice. This study provides a reference for the development and immunization of ASF vaccines with <italic toggle="yes">L. lactis</italic> as live carriers.</p></abstract><kwd-group><kwd>African swine fever virus</kwd><kwd><italic toggle="yes">Lactococcus lactis</italic></kwd><kwd>immunogenicity</kwd><kwd>mouse model</kwd></kwd-group><funding-group><award-group><funding-source>the National Key Research and Development Program of China in the 14th Five-Year Period</funding-source><award-id>2021YFD1801403</award-id></award-group><funding-statement>This research was supported by the National Key Research and Development Program of China in the 14th Five-Year Period (grant no. 2021YFD1801403).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00140"><title>1. Introduction</title><p>African swine fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious and hemorrhagic disease. It exhibits a diverse spectrum of clinical manifestations, ranging from chronic to peracute forms, and poses a significant threat to the stability and development of the global swine industry stability [<xref rid="B1-vetsci-12-00140" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00140" ref-type="bibr">2</xref>]. To mitigate ASF-associated losses, the development of safe and efficacious vaccines is imperative. The current landscape of ASF vaccine development encompasses various strategies, such as inactivated vaccines, live-attenuated vaccines, subunit vaccines, and live vector vaccines [<xref rid="B3-vetsci-12-00140" ref-type="bibr">3</xref>,<xref rid="B4-vetsci-12-00140" ref-type="bibr">4</xref>,<xref rid="B5-vetsci-12-00140" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-12-00140" ref-type="bibr">6</xref>,<xref rid="B7-vetsci-12-00140" ref-type="bibr">7</xref>]. However, these vaccine strategies still face some limitations that necessitate addressing. For instance, while live-attenuated ASF vaccines are perceived to exhibit better efficacy, they entail higher safety risks due to potential residual virulence [<xref rid="B8-vetsci-12-00140" ref-type="bibr">8</xref>,<xref rid="B9-vetsci-12-00140" ref-type="bibr">9</xref>]. Conversely, subunit ASF vaccines have higher safety, but their protective efficacy still requires improvement [<xref rid="B10-vetsci-12-00140" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00140" ref-type="bibr">11</xref>]. Therefore, there is a need for continued research and development to address these challenges and ultimately produce a safe and effective ASF vaccine.</p><p>ASFV is a double-stranded DNA virus and the sole known tick-borne DNA virus [<xref rid="B12-vetsci-12-00140" ref-type="bibr">12</xref>]. The genome of ASFV spans a size range of 170 to 194 kilobase pairs (kb) and contains between 151 and 167 open reading frames (ORFs) [<xref rid="B13-vetsci-12-00140" ref-type="bibr">13</xref>]. ASFV encodes over 60 structural proteins and 100 non-structural proteins, which provide significant assistance in its assembly, replication, repair, and immune evasion [<xref rid="B14-vetsci-12-00140" ref-type="bibr">14</xref>]. Although the functions of some of these proteins remain unclear, numerous immunogenic candidate protective antigens have been identified. Among them, the ASFV p72 (encoded by the <italic toggle="yes">B646L</italic> gene), p54 (encoded by the <italic toggle="yes">E183L</italic> gene), p30 (encoded by the <italic toggle="yes">CP204L</italic> gene), and CD2v (encoded by the <italic toggle="yes">EP402R</italic> gene) proteins are the most commonly used protective antigen targets for ASF [<xref rid="B15-vetsci-12-00140" ref-type="bibr">15</xref>,<xref rid="B16-vetsci-12-00140" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-12-00140" ref-type="bibr">17</xref>]. Furthermore, researchers systematically evaluated the immune responses of pigs to individual ASFV antigens by priming with a DNA vaccine via delivery of individual genes, followed by booster immunization using a recombinant vaccinia virus vector. They conducted an exhaustive screening of approximately 30% of ASFV antigens. The results indicated that the D117L and E120R proteins have potential as significant inducers of protective antibody responses or as serological markers of infection. Additionally, the F317L, B602L, p72, p54, and CD2v proteins were found to effectively stimulate specific lymphocytes in immunized pigs, eliciting a robust cellular immune response [<xref rid="B18-vetsci-12-00140" ref-type="bibr">18</xref>].</p><p><italic toggle="yes">Lactococcus lactis</italic>, owing to its safety and ability to induce mucosal immune responses, has been widely employed in the development of mucosal vaccines. <italic toggle="yes">L. lactis</italic>, a well-studied lactic acid bacteria (LAB), holds the generally recognized as safe (GRAS) status due to its extensive history of use in human food fermentations and products [<xref rid="B19-vetsci-12-00140" ref-type="bibr">19</xref>]. This makes <italic toggle="yes">L. lactis</italic> widely used, including as a carrier for mucosal vaccines to present bacterial and viral antigens [<xref rid="B20-vetsci-12-00140" ref-type="bibr">20</xref>]. The nisin-controlled gene expression (NICE) system, a tightly regulated inducible expression platform, enables precise heterologous protein production in <italic toggle="yes">L. lactis</italic>, facilitating its genetic engineering for vaccinology [<xref rid="B21-vetsci-12-00140" ref-type="bibr">21</xref>]. Numerous studies have demonstrated the potential of <italic toggle="yes">L. lactis</italic> as a vaccine vector. For instance, recombinant <italic toggle="yes">L. lactis</italic> (r<italic toggle="yes">L. lactis</italic>) expressing multi-epitope antigens of foot-and-mouth disease virus (FMDV) serotype A was found to effectively induce the production of secretory IgA (sIgA) and IgG in mucosal tissues while also eliciting robust cellular immune responses [<xref rid="B22-vetsci-12-00140" ref-type="bibr">22</xref>]. In addition, <italic toggle="yes">L. lactis</italic> activates innate immune pathways, as evidenced by strain <italic toggle="yes">L. lactis</italic>-pNZ8148-BLS-Usp45, which expresses the <italic toggle="yes">Brucella</italic> LS protein, induced IgG antibodies and high levels of cytokines, such as interferon gamma (IFN-<italic toggle="yes">&#x003b3;</italic>), tumor necrosis factor alpha (TNF-<italic toggle="yes">&#x003b1;</italic>), interleukin 4 (IL-4), and IL-10 [<xref rid="B23-vetsci-12-00140" ref-type="bibr">23</xref>]. Another study showed that using <italic toggle="yes">L. lactis</italic> as an oral vaccine delivery vector to express the VP6 protein of grass carp reovirus type II resulted in significant increases in the survival rate (46.7%) and protection rate (42.9%) compared with the control groups [<xref rid="B24-vetsci-12-00140" ref-type="bibr">24</xref>]. Researchers have also constructed r<italic toggle="yes">L. lactis</italic> strains capable of expressing <italic toggle="yes">Eimeria tenella</italic> immune mapped protein-1 (EtIMP1), a protective antigen against coccidiosis in chickens. Animal trials showed that compared to <italic toggle="yes">L. lactis</italic> carrying the parental vector, all three strains expressing EtIMP1 significantly reduced oocyst shedding, mitigated pathological changes in the cecum, and improved weight gain [<xref rid="B25-vetsci-12-00140" ref-type="bibr">25</xref>].</p><p>In this study, we selected eight immunogenic proteins of ASFV (F317L, H171R, D117L, E120R, B602L, CD2v, p54, and p72) to construct ASF vaccine candidates using <italic toggle="yes">L. lactis</italic> as a vector, and then evaluated the immune responses of these vaccine candidates in mice through both oral gavage and intramuscular injection routes. The objective was to establish a foundation for developing an oral vaccine using <italic toggle="yes">L. lactis</italic> as a carrier. By exploring the immune response capabilities induced by these r<italic toggle="yes">L. lactis</italic> strains, we aim to present new ideas and directions for advancing the development of an ASF vaccine.</p></sec><sec id="sec2-vetsci-12-00140"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00140"><title>2.1. Bacterial Strains, Plasmids, and Target DNAs</title><p>The nisin-inducible expression plasmid pNZ8149 and the <italic toggle="yes">L. lactis</italic> NZ3900 strain used in this study were generously provided by Dr. Hongyu Cui at the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS). The pNZ8149 plasmid is non-resistant, and the recombinant bacterial strains harboring pNZ8149 plasmid were screened by using a lactose-containing medium. The gene sequence of the ASFV HLJ/18 strain (accession number: MK333180.1) was retrieved from the GenBank database and optimized based on the whole genome sequence of the <italic toggle="yes">L. lactis</italic> MG1363 strain (the parental strain of <italic toggle="yes">L. lactis</italic> NZ3900). The optimized ASFV gene sequences were then synthesized by Nanjing GenScript.</p></sec><sec id="sec2dot2-vetsci-12-00140"><title>2.2. Construction of the Recombinant Plasmids</title><p>The primers listed in <xref rid="vetsci-12-00140-t001" ref-type="table">Table 1</xref> were used to amplify the linearized vector fragments from pNZ8149 and the target genes for ASFV. The resulting DNA fragments were separated by agarose gel electrophoresis and purified using a gel extraction kit (Omega, Norcross, GA, USA). The purified fragments were then subjected to homologous recombination using the ClonExpress II One Step cloning kit (Vazyme Biotech Co., Nanjing, China) to construct the recombinant plasmid [<xref rid="B26-vetsci-12-00140" ref-type="bibr">26</xref>].</p></sec><sec id="sec2dot3-vetsci-12-00140"><title>2.3. Construction of the Recombinant L. lactis</title><p>The electrocompetent cells of the <italic toggle="yes">L. lactis</italic> NZ3900 strain were prepared following the method described previously [<xref rid="B27-vetsci-12-00140" ref-type="bibr">27</xref>]. Subsequently, <italic toggle="yes">L. lactis</italic> electrocompetent cells were chilling on ice until they were fully thawed. A total of 10 &#x003bc;L of the recombinant plasmid DNA was gently mixed with 50 &#x003bc;L of electrocompetent cells and incubated on ice for 2 min. Thereafter, the mixture was transferred into a pre-cooled 0.2-cm electroporation cuvette. The electroporation settings were adjusted to deliver a single pulse of 2000 V, 25 &#x003bc;F, and 200 &#x003a9;, with a single electrical pulse duration of 4 to 5 ms. Post-electroporation, the cells were promptly resuspended in 700 &#x003bc;L of pre-cooled GM17 broth (supplemented with 20 mM of MgCl<sub>2</sub> and 2 mM of CaCl<sub>2</sub>), and placed on ice for 5 min. Activation ensued in a 30&#x000b0;C incubator over a period of 1 h. Following this, the culture was centrifuged at 6000<italic toggle="yes">&#x000d7; g</italic> for 2 min and resuspended in 50 &#x003bc;L of fresh GM17 medium. The resuspended cells were plated onto lactose-supplemented EM agar medium and statically incubated in a 30&#x000b0;C incubator for 24 to 48 h. Subsequently, single colonies were streaked onto fresh selective plates for purity verification prior to overnight culture in GM17 at 30&#x000b0;C. The plasmids were extracted for gene sequencing, and the r<italic toggle="yes">L. lactis</italic> strains with correctly matched sequences were preserved at &#x02212;80&#x000b0;C for future use.</p></sec><sec id="sec2dot4-vetsci-12-00140"><title>2.4. Western Blotting</title><p>To determine the subcellular localization of the recombinant proteins expression, the r<italic toggle="yes">L. lactis</italic> strains were induced with nisin to express the ASFV proteins, lysed by ultrasonication, and then fractionated into soluble (supernatant) and insoluble (precipitate) fractions by centrifugation. Equal volumes of 40 &#x000b5;L of the supernatant and precipitate were mixed with 10 &#x000b5;L of 5&#x000d7; sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer and boiled for 10 min. The samples were then subjected to SDS-PAGE separation and subsequently transferred onto a nitrocellulose membrane. The membrane was incubated with mouse anti-Strep antibodies (1:2000) as the primary antibody, followed by a goat anti-mouse IgG antibody (1:10,000) (Abcam, Cambridge, UK) as the secondary antibody. The blots were subsequently scanned using the Odyssey scanning imaging system.</p></sec><sec id="sec2dot5-vetsci-12-00140"><title>2.5. Growth Curve of rL. lactis Strains</title><p>In order to evaluate the growth characteristics of the eight r<italic toggle="yes">L. lactis</italic> strains, we selected r<italic toggle="yes">L. lactis</italic>-F317L as a model organism. Overnight cultures of r<italic toggle="yes">L. lactis</italic>-F317L, <italic toggle="yes">L. lactis</italic>-pNZ8149 (strain containing an empty vector plasmid), and <italic toggle="yes">L. lactis</italic> NZ3900 (plasmid-free strain) were inoculated into EM broth at a 1:20 dilution ratio. Both induced and non-induced groups were established. The optical density at 600 nm (OD<sub>600nm</sub>) values of the cultures were measured initially, and subsequently recorded at hourly intervals until the bacterial stationary phase was reached. Utilizing these data points, growth curves were drawn for the r<italic toggle="yes">L. lactis</italic>-F317L, <italic toggle="yes">L. lactis</italic>-pNZ8149, and <italic toggle="yes">L. lactis</italic> NZ3900 under both the induced and non-induced conditions.</p></sec><sec id="sec2dot6-vetsci-12-00140"><title>2.6. Immunization of Mice</title><p>A total of 20 specific-pathogen-free (SPF) six-week-old BALB/c mice were randomly divided into 4 groups, with 5 mice per group, as follows: (A) in the r<italic toggle="yes">L. lactis</italic> oral gavage group, each mouse was oral gavage-immunized with 8 &#x000d7; 10<sup>9</sup> colony forming units (CFU) of a mixture of r<italic toggle="yes">L. lactis</italic>-F317L, r<italic toggle="yes">L. lactis</italic>-H171R, r<italic toggle="yes">L. lactis</italic>-D117L, r<italic toggle="yes">L. lactis</italic>-E120R, r<italic toggle="yes">L. lactis</italic>-B602L, r<italic toggle="yes">L. lactis</italic>-CD2v, r<italic toggle="yes">L. lactis</italic>-p54, and r<italic toggle="yes">L. lactis</italic>-p72 at a dose of 10<sup>9</sup> CFU per strain; this mixture was termed the r<italic toggle="yes">L. lactis</italic>-mix; (B) in the r<italic toggle="yes">L. lactis</italic> intramuscular group, the immunogen and immunization doses were the same as in group A, but immunization was carried out through intramuscular injection; (C) in the <italic toggle="yes">L. lactis</italic>-pNZ8149 group, each mouse was oral gavage-immunized with 8 &#x000d7; 10<sup>9</sup> CFU of <italic toggle="yes">L. lactis</italic>-pNZ8149; (D) in the PBS group, each mouse oral gavage-immunized with 200 &#x003bc;L of PBS. Among them, the r<italic toggle="yes">L. lactis</italic> intramuscular group was intramuscularly injected after the strains were inactivated, and the other groups of strains were immunized with live bacteria via oral gavage immunization. The immunization schedules are shown in <xref rid="vetsci-12-00140-t002" ref-type="table">Table 2</xref>.</p><p>The immunization schedule for the mice comprised the following steps: primary immunization, followed by oral gavage immunization on the subsequent day for a continuous period of 14 d. Two weeks later, a booster immunization was administered via oral gavage for three consecutive days. After another two weeks, a second booster immunization was given for three days. Each immunization was accompanied by a single intramuscular injection. Blood samples were collected from the orbital venous plexus on Day 0, Day 21 (7 d post-primary immunization), Day 37 (7 d post-first booster immunization), Day 44 (14 d post-first booster immunization), and Day 54 (7 days post-second booster immunization). On Day 54, the mice were anesthetized with CO<sub>2</sub> and euthanized by cervical dislocation. Their spleens were harvested for subsequent lymphocyte proliferation assays.</p></sec><sec id="sec2dot7-vetsci-12-00140"><title>2.7. Enzyme-Linked Immunosorbent Assay (ELISA)</title><p>Blood and feces samples of the mice were collected at various time points post-immunization. The collected blood samples were placed in a 37&#x000b0;C incubator for 2 h and centrifuged at 1000<italic toggle="yes">&#x000d7; g</italic> for 15 min. The supernatant obtained, which is the serum, was collected for the next detection. Regarding the feces samples, they were first weighed, and 0.4 mL of feces extract (prepared with 0.05 M EDTA-Na2 solution in PBS) was added to each 0.1 g feces. After shaking for 10 min, it was placed overnight at 4&#x000b0;C, centrifuged at 12,000<italic toggle="yes">&#x000d7; g</italic> for 5 min, and the supernatant was collected for the next detection. We used the prokaryotic expression system to express and purify the eight ASFV proteins in this study, with <italic toggle="yes">Escherichia coli</italic> Rosetta as the expression host and the pCold-TF plasmid as the expression plasmid.</p><p>The 96-well microplates were coated with the purified ASFV protein and incubated at 4&#x000b0;C overnight. Then, each well was washed three times with 200 &#x003bc;L of PBS containing 0.05% tween 20 (PBST). After washing, 150 &#x003bc;L of blocking solution (5% skimmed milk) was added to each well and incubated in a 37&#x000b0;C incubator for 2 h. The blocking solution was then discarded, and the microplates were dried. Next, 100 &#x003bc;L of the treated serum samples or fecal supernatants were added to the microplates (using reference anti-ASFV sera as the positive control and SPF pig sera as the negative control), and they were incubated in a 37&#x000b0;C incubator for 1 h. After incubation, the microplates were washed five times with PBST, 3 min each time, and then dried. Subsequently, 100 &#x003bc;L of HRP-conjugated rabbit anti-mouse IgG or goat anti-mouse IgA (Abcam, Cambridge, UK) was added into each well (the control sera were used with goat anti-pig IgG), and the microplates were incubated in a 37&#x000b0;C incubator for 45 min. After incubation, the microplates were washed five times with PBST for 3 min each time. The tetramethylbenzidine (TMB) chromogenic solution was added, 100 &#x003bc;L per well, and the microplates were kept at room temperature in the dark for 15 min. The reaction was stopped by adding 50 &#x003bc;L of 2 M H<sub>2</sub>SO<sub>4</sub> to each well [<xref rid="B28-vetsci-12-00140" ref-type="bibr">28</xref>]. The concentrations of cytokines IL-2, IL-4, IL-10, and IFN-<italic toggle="yes">&#x003b3;</italic> in the sera were quantified using a commercially available ELISA kit (Cloud-Clone, Wuhan, China).</p></sec><sec id="sec2dot8-vetsci-12-00140"><title>2.8. Spleen Lymphocytes Proliferation Test</title><p>Spleen lymphocytes separation medium (TBD, Tianjin, China) was used to isolate the spleen lymphocytes of the mice after euthanasia. In brief, the splenic lymphocytes were suspended in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 5% penicillin/streptomycin (Gibco, Waltham, MA, USA). The cells were then cultured in 96-well microplates at a density of 5 &#x000d7; 10<sup>6</sup> cells per mL with 50 &#x003bc;L/well. The splenic lymphocytes were stimulated with 10<sup>5</sup> TCID<sub>50</sub> ASFV as a specific antigen stimulation, concanavalin A (ConA) (10 &#x003bc;g/mL) as a positive control, and RPMI-1640 medium as a negative control, respectively. The plates were then incubated for 72 h in a 5% CO<sub>2</sub> incubator at 37&#x000b0;C. To assess the proliferation responses of the splenic lymphocytes, the cell counting kit-8 (CCK-8) assay (Ape&#x000d7;Bio, Houston, TX, USA) was used, after incubation at 37&#x000b0;C in an incubator in the dark for 3 h, the absorbance at 450 nm was read on a microplate reader. The data were presented as stimulation indices (SI), calculated as the ratio of the (stimulated value &#x02212; blank value)/(unstimulated value &#x02212; blank value).</p></sec><sec id="sec2dot9-vetsci-12-00140"><title>2.9. Statistical Analysis</title><p>The results are presented as the means &#x000b1; standard deviations (SDs). Statistical evaluations were conducted using GraphPad Prism version 9. To discern statistically significant variations among the various groups, a one-way analysis of variance (ANOVA) was employed, and in the text, ns denotes <italic toggle="yes">p</italic> &#x02265; 0.05, indicating no significance, * denotes <italic toggle="yes">p</italic> &#x0003c; 0.05, ** denotes <italic toggle="yes">p</italic> &#x0003c; 0.01, *** denotes <italic toggle="yes">p</italic> &#x0003c; 0.001, and **** denotes <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00140"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00140"><title>3.1. Eight rL. lactis Strains Enabled Soluble Expression of Corresponding ASFV Antigens</title><p>The plasmid used to express the antigens of ASFV is pNZ8149, which can induce the expression of exogenous proteins in the presence of nisin. Given that the fusion of eight genes encoding ASFV antigens into a single plasmid might complicate the plasmid construction process and potentially impair the expression of the proteins, we constructed eight recombinant plasmids, each expressing only one ASFV antigen. However, the construction methods for these plasmids were largely similar. In summary, we obtained a linearized plasmid, pNZ8149, through inverse PCR and subsequently generated recombinant plasmids by performing homologous recombination between the amplified eight ASFV genes and the linearized pNZ8149, respectively (<xref rid="vetsci-12-00140-f001" ref-type="fig">Figure 1</xref>a). To assess the expression levels and localization of the eight ASFV antigens, the r<italic toggle="yes">L. lactis</italic> strains expressing the respective ASFV antigens were induced with nisin. Subsequently, we analyzed the expression of the ASFV antigens in both the supernatant and precipitate of the ultrasonically lysed samples by Western blotting. The results demonstrate that all eight proteins, ASFV F317L (40 kDa), H171R (24 kDa), D117L (16 kDa), E120R (20 kDa), B602L (71 kDa), CD2v (43 kDa), p54 (22 kDa), and p72 (75 kDa), could be expressed in a soluble form (<xref rid="vetsci-12-00140-f001" ref-type="fig">Figure 1</xref>b).</p></sec><sec id="sec3dot2-vetsci-12-00140"><title>3.2. Stable Inheritance of Recombinant Plasmids Without Affecting Bacterial Strain Growth</title><p>In order to evaluate the growth characteristics of the eight constructed r<italic toggle="yes">L. lactis</italic> strains, the growth curve of r<italic toggle="yes">L. lactis</italic>-F317L was assessed as the model strain. The OD<sub>600nm</sub> values of r<italic toggle="yes">L. lactis</italic>-F317L, <italic toggle="yes">L. lactis</italic>-pNZ8149, and <italic toggle="yes">L. lactis</italic> NZ3900 were measured and recorded at 1 h intervals. This monitoring was continued until the bacteria reached the stationary phase, following which growth curves were plotted based on the collected data. The results show that there was no significant difference in the growth characteristics between the recombinant strain and the parental strain (<xref rid="vetsci-12-00140-f002" ref-type="fig">Figure 2</xref>a). To verify the genetic stability of the r<italic toggle="yes">L. lactis</italic> strains, serial passages were conducted. At the 22nd generation, the r<italic toggle="yes">L. lactis</italic> strains were induced to express the corresponding ASFV antigens, and the expressions of these proteins were confirmed by Western blotting. The results indicate that the eight r<italic toggle="yes">L. lactis</italic> strains exhibited robust genetic stability. Specifically, at the 22nd generation, none of the recombinant plasmids had been lost, and stable expression of the eight ASFV antigens (F317L, H171R, D117L, E120R, B602L, CD2v, p54, and p72) was maintained (<xref rid="vetsci-12-00140-f002" ref-type="fig">Figure 2</xref>b).</p></sec><sec id="sec3dot3-vetsci-12-00140"><title>3.3. Intramuscular Injection of rL. lactis-Mix Induced High-Level Serum IgG Antibodies in Immunized Mice</title><p>To evaluate the immunogenic efficacy of the r<italic toggle="yes">L. lactis</italic>-mix, experimental mice were immunized with the 8 &#x000d7; 10<sup>9</sup> CFU of r<italic toggle="yes">L. lactis</italic>-mix through intramuscular injection and oral gavage. Additionally, the <italic toggle="yes">L. lactis</italic>-pNZ8149 group mice were immunized with 8 &#x000d7; 10<sup>9</sup> CFU of <italic toggle="yes">L. lactis</italic>-pNZ8149 via oral gavage, while the PBS group mice were immunized with 200 &#x003bc;L of PBS administered oral gavage. Sera and fecal samples were collected from the immunized mice at various time points (<xref rid="vetsci-12-00140-f003" ref-type="fig">Figure 3</xref>a). In this study, the eight ASFV antigens were expressed and purified by prokaryotic expression system, and an indirect ELISA detection method was established to detect the specific IgG antibodies in the sera of immunized mice. The results show that the r<italic toggle="yes">L. lactis</italic> intramuscular immunization induced high-level serum IgG antibodies 7 d post-primary immunization, which were maintained until 7 d post-second booster immunization. Unfortunately, the mice in the oral gavage group did not exhibit a significant increase in sera antibodies compared with the control group (<xref rid="vetsci-12-00140-f003" ref-type="fig">Figure 3</xref>b).</p></sec><sec id="sec3dot4-vetsci-12-00140"><title>3.4. Oral Gavage of rL. lactis-Mix Induced High-Level sIgA Antibodies in Immunized Mice at the Early Stage of Immunization</title><p>In order to evaluate the mucosal immune responses induced by the r<italic toggle="yes">L. lactis</italic>-mix, the feces of the immunized mice were collected at various time points, and the level of sIgA antibodies in the feces were detected by ELISA. The results show that sIgA antibodies were present in the feces of mice oral gavage with the r<italic toggle="yes">L. lactis</italic>-mix at 7 d after the primary immunization. However, in the fecal samples collected at the subsequent time points, the level of sIgA in the fecal samples of the r<italic toggle="yes">L. lactis</italic>-mix oral gavage group decreased to having no significant difference from that of the control group. Furthermore, there was no significant difference in the level of sIgA antibodies in feces between the r<italic toggle="yes">L. lactis</italic>-mix intramuscular injection group and the control group (<xref rid="vetsci-12-00140-f004" ref-type="fig">Figure 4</xref>). Given that the intestinal mucosa provides a more precise indication of mouse intestinal sIgA levels, intestinal mucosal samples were collected from euthanized mice, and their sIgA levels were evaluated. The results show no significant difference in the level of intestinal mucosal sIgA between the mice in the r<italic toggle="yes">L. lactis</italic>-mix oral gavage group and the control group (<xref rid="app1-vetsci-12-00140" ref-type="app">Figure S1</xref>).</p></sec><sec id="sec3dot5-vetsci-12-00140"><title>3.5. Intramuscular Injection of rL. lactis-Mix Elevated Sera IFN-&#x003b3; and IL-10 in Immunized Mice</title><p>In order to evaluate the effect of the r<italic toggle="yes">L. lactis</italic>-mix immunization on the innate immunity of mice, we evaluated the levels of cytokines, including IL-2, IL-4, IL-10, and IFN-&#x003b3; in the sera of mice. IFN-&#x003b3; and IL-2 are cytokines produced by Th1 cells, which can promote the activation and proliferation of cytotoxic T lymphocytes (CTLs), macrophages, and NK cells and enhance the number of CD8<sup>+</sup> T cells and innate immune responses. IL-4 and IL-10 belong to Th2 cytokine subset, which promote B cell proliferation and differentiation into plasma cells, thereby initiating antibody secretion, enhancing humoral immune response, and inhibiting inflammation. The results show that the levels of both IFN-&#x003b3; and IL-10 in the sera of the mice in the r<italic toggle="yes">L. lactis</italic>-mix intramuscular injection group were significantly higher compared with those in the other groups (<xref rid="vetsci-12-00140-f005" ref-type="fig">Figure 5</xref>).</p><p>To further evaluate the level of cellular immune response mediated by the mice immunized with the r<italic toggle="yes">L. lactis</italic>-mix, we determined the proliferation of spleen lymphocytes in the mice. Lymphocyte proliferation serves as an indicator of lymphocyte activity and functional status in response to relevant stimuli. The results show that there was no significant difference in the stimulation index of spleen lymphocytes among the four groups of mice spleen lymphocyte stimulated with 10<sup>5</sup> TCID<sub>50</sub> ASFV (<xref rid="app1-vetsci-12-00140" ref-type="app">Figure S2</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00140"><title>4. Discussion</title><p>Given the persistent threat posed by ASF to the global pig industry, the development of effective and safe vaccines has become a matter of urgency. Various strategies have been explored for developing ASF vaccines, yet each approach harbors distinct limitations [<xref rid="B29-vetsci-12-00140" ref-type="bibr">29</xref>]. ASFV naturally infects pigs primarily through contact or aerosols, breaching the mucosal barrier and leading to disease onset [<xref rid="B30-vetsci-12-00140" ref-type="bibr">30</xref>]. Currently, ASF vaccine candidates are predominantly designed for intramuscular administration, which typically fails to elicit a mucosal immune response. Consequently, recombinant ASF vaccines employing <italic toggle="yes">L. lactis</italic> may offer a promising approach to prevent ASFV invasion during the early stages of infection. In this study, we constructed eight r<italic toggle="yes">L. lactis</italic> strains expressing ASFV antigens by utilizing the NICE expression system. These eight r<italic toggle="yes">L. lactis</italic> strains included r<italic toggle="yes">L. lactis</italic>-F317L, r<italic toggle="yes">L. lactis</italic>-H171R, r<italic toggle="yes">L. lactis</italic>-D117L, r<italic toggle="yes">L. lactis</italic>-E120R, r<italic toggle="yes">L. lactis</italic>-B602L, r<italic toggle="yes">L. lactis</italic>-CD2v, r<italic toggle="yes">L. lactis</italic>-p54, and r<italic toggle="yes">L. lactis</italic>-p72. Subsequently, a mixture of these eight r<italic toggle="yes">L. lactis</italic> strains was administered to mice via both intramuscular injection and oral gavage for immunization.</p><p>The results indicate that intramuscular injection of the r<italic toggle="yes">L. lactis</italic>-mix successfully elicited high-level IgG antibodies in the sera of mice, whereas oral gavage administration of the same r<italic toggle="yes">L. lactis</italic>-mix failed to induce specific IgG antibody production in the sera. This discrepancy could be attributed to the intracellular localization of the recombinant proteins, which might hinder efficient recognition and capture of the vaccine antigens by the intestinal mucosal epithelium, thereby impeding the induction of an effective immune response. In contrast, the r<italic toggle="yes">L. lactis</italic>-mix in the intramuscular injection group was disrupted by ultrasound, making the proteins more accessible to immune cells in the bloodstream and subsequently stimulating an immune response. Consistent with our findings, previous researchers constructed the r<italic toggle="yes">L. lactis</italic>-OptiVP2-RCK, which co-expressed the primary antigen VP2 of infectious bursal disease virus and the RCK protein of an intestinal <italic toggle="yes">Salmonella</italic> strain. Despite detecting no specific IgG antibodies in the sera following oral gavage immunization, neutralizing antibodies were present and conferred protection to chickens [<xref rid="B31-vetsci-12-00140" ref-type="bibr">31</xref>]. The authors speculated that differences in protein structure, as well as distinctions between mucosal and systemic immunity, could account for these observations.</p><p>The utilization of <italic toggle="yes">L. lactis</italic> as a vaccine vector is notably advantageous due to its capacity to induce mucosal immune responses via mucosal immunization. sIgA, the predominant antibody in mucosal secretions, offers protection against pathogen adhesion and intestinal barrier penetration. In this study, we observed a significant elevation in sIgA antibody levels in the feces of the mice immunized via oral gavage with the r<italic toggle="yes">L. lactis</italic>-mix on the 7 d post-primary immunization. However, following booster immunization, the sIgA levels in the feces of these mice decreased, showing no significant difference compared with the control groups. This decline may be attributed to the early-secreted nature of sIgA, as studies suggest its primary role during the initial secretory phase of immunization [<xref rid="B32-vetsci-12-00140" ref-type="bibr">32</xref>]. In contrast to systemic immunity, the mucosal immune system not only defends against pathogenic microorganisms but also tolerates a plethora of antigens and normal flora present in food [<xref rid="B33-vetsci-12-00140" ref-type="bibr">33</xref>]. The quantity, nature of the antigen, and the frequency of immunizations are crucial factors influencing the development of immune tolerance [<xref rid="B34-vetsci-12-00140" ref-type="bibr">34</xref>]. Oral immunization with small, soluble antigen doses has been demonstrated to potentially induce a reduction in host cellular immunity and the production of immune tolerance [<xref rid="B35-vetsci-12-00140" ref-type="bibr">35</xref>,<xref rid="B36-vetsci-12-00140" ref-type="bibr">36</xref>]. Therefore, the low-level expression of the ASFV antigen protein by r<italic toggle="yes">L. lactis</italic>, combined with the prolonged immune stimulation from the primary immunization, may have led to the induction of immune tolerance in the mouse intestinal tract. This could explain why the sIgA antibody levels in the feces of the immunized mice decreased to levels indistinguishable from those of the control group during the later stages of immunization and failed to stimulate an increase in lymphocyte proliferation.</p><p>Cytokines are small molecular proteins exhibiting diverse biological activities, produced by both immune and certain non-immune cells [<xref rid="B37-vetsci-12-00140" ref-type="bibr">37</xref>]. Serving as cellular signaling molecules, they regulate immune responses, participate in the differentiation and development of immune cells, mediate inflammatory reactions, stimulate hematopoiesis, and facilitate tissue repair. Specifically, cytokines such as IL-2 and IFN-<italic toggle="yes">&#x003b3;</italic>, secreted by Th1 cells, augment the activation and proliferation of CTLs, macrophages, and NK cells, thereby augmenting cytotoxicity against infected cells, enhancing phagocytic activity, and strengthening CD8<sup>+</sup> T cell and innate immune responses. Conversely, IL-10 and IL-4 produced by Th2 cells promote the proliferation and differentiation of B cells into plasma cells, initiating antibody secretion and fostering humoral immune responses. Numerous studies have demonstrated the potential of utilizing <italic toggle="yes">L. lactis</italic> as a carrier to enhance both Th1 and Th2 immune responses. For instance, oral administration of pNZ8149-S1/NZ3900 expressing the S1 protein of porcine epidemic diarrhea virus (PEDV) can induce high levels of IL-4 and IFN-<italic toggle="yes">&#x003b3;</italic> in the sera of immunized mice [<xref rid="B38-vetsci-12-00140" ref-type="bibr">38</xref>], and using <italic toggle="yes">L. lactis</italic> as a carrier to express the gD protein of Herpes simplex virus type 1 (HSV-1) can also significantly elevate the levels of IFN-<italic toggle="yes">&#x003b3;</italic> in the serum of immunized mice [<xref rid="B39-vetsci-12-00140" ref-type="bibr">39</xref>]. Similar to previous studies, oral gavage of the r<italic toggle="yes">L. lactis</italic>-mix induced higher levels of IFN-<italic toggle="yes">&#x003b3;</italic> and IL-10 production in the sera of mice.</p><p>Concurrently, it is recognized as a limitation of this study that the immunogenicity and protective efficacy of these eight r<italic toggle="yes">L. lactis</italic> strains were not assessed in pigs. However, our findings provide valuable insights into the development of ASF mucosal vaccines based on <italic toggle="yes">L. lactis</italic>. The results indicate that oral gavage immunization can elicit the production of sIgA, potentially providing early protection to pigs, whereas intramuscular immunization more effectively induces the generation of serum-specific IgG antibodies. Furthermore, more experimental animals are needed to obtain more accurate and statistically significant data. Increasing the number of immunized mice may enhance the immune data mediated by r<italic toggle="yes">L. lactis</italic>. We hypothesize that surface-displayed antigens may enhance the immunogenicity by presenting antigens on the surface of the <italic toggle="yes">L. lactis</italic>, thereby increasing the chances of antigen capture by antigen-presenting cells (APCs) and potentially amplifying the initiation of immune responses. Additionally, increasing the expression levels of ASFV antigens could further boost the immunogenic properties of the vaccines.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00140"><title>5. Conclusions</title><p>In this study, we constructed eight pools of r<italic toggle="yes">L. lactis</italic> strains, each expressing different antigens of ASFV, and evaluated the immune responses induced by these strains through oral gavage and intramuscular injection in a mouse model. The results demonstrate that the intramuscular injection group induced high levels of serum-specific IgG antibodies and significantly elevated the levels of IFN-<italic toggle="yes">&#x003b3;</italic> and IL-10 in the serum. In the oral gavage immunization group, a transient increase in the sIgA antibody level was observed in fecal samples 7 d after the primary immunization. This indicates that these antigens possess good immunogenicity and that the multi-antigen cocktail vaccination is safe for mice. This study provides a reference for the development and immunization of ASF vaccines using <italic toggle="yes">Lactobacillus</italic> as a live vector.</p></sec></body><back><ack><title>Acknowledgments</title><p>Thank you to the staff of the Animal Experiments of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences for their help in our research, and especially to Hongyu Cui for gifting the host strain.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00140"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020140/s1">https://www.mdpi.com/article/10.3390/vetsci12020140/s1</uri>, Figure S1: The sIgA antibodies in the intestinal mucosa of the immunized mice; Figure S2: T lymphocyte proliferation of the immunized mice.</p><supplementary-material id="vetsci-12-00140-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00140-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, Y.S., H.W. and J.H.; validation, J.H. and H.W.; data curation, Y.S.; formal analysis, H.-J.Q., Y.S., J.H. and H.W.; funding acquisition, H.W. and Y.S.; investigation, J.H., H.W., T.G., D.Z., M.L., Z.L. and Y.L.; methodology, Y.S., H.W. and J.H.; project administration, H.W. and Y.S.; supervision, Y.S. and H.W.; writing&#x02014;original draft, J.H.; writing&#x02014;review and editing, H.-J.Q., J.H., Y.S., H.W., T.G., D.Z., M.L., Z.L. and Y.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Committee on the Ethics of Animal Experiments of the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS) of China (No. 220802-02-GR).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The dataset is available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00140"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>E.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Ding</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Shen</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Ren</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Highly lethal genotype I and II recombinant African swine fever viruses detected in pigs</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>3096</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38868-w</pub-id><pub-id pub-id-type="pmid">37248233</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00140"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Penrith</surname><given-names>M.L.</given-names></name>
<name><surname>Kivaria</surname><given-names>F.M.</given-names></name>
</person-group><article-title>One hundred years of African swine fever in Africa: Where have we been, where are we now, where are we going?</article-title><source>Transbound. Emerg. Dis.</source><year>2022</year><volume>69</volume><fpage>e1179</fpage><lpage>e1200</lpage><pub-id pub-id-type="doi">10.1111/tbed.14466</pub-id><pub-id pub-id-type="pmid">35104041</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00140"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blome</surname><given-names>S.</given-names></name>
<name><surname>Gabriel</surname><given-names>C.</given-names></name>
<name><surname>Beer</surname><given-names>M.</given-names></name>
</person-group><article-title>Modern adjuvants do not enhance the efficacy of an inactivated African swine fever virus vaccine preparation</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3879</fpage><lpage>3882</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.05.051</pub-id><pub-id pub-id-type="pmid">24877766</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00140"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Shan</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs</article-title><source>Sci. China Life Sci.</source><year>2020</year><volume>63</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1007/s11427-020-1657-9</pub-id><pub-id pub-id-type="pmid">32124180</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00140"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borca</surname><given-names>M.V.</given-names></name>
<name><surname>Ramirez-Medina</surname><given-names>E.</given-names></name>
<name><surname>Silva</surname><given-names>E.</given-names></name>
<name><surname>Vuono</surname><given-names>E.</given-names></name>
<name><surname>Rai</surname><given-names>A.</given-names></name>
<name><surname>Pruitt</surname><given-names>S.</given-names></name>
<name><surname>Holinka</surname><given-names>L.G.</given-names></name>
<name><surname>Velazquez-Salinas</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Gladue</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Development of a highly effective African swine fever virus vaccine by deletion of the <italic toggle="yes">I177l</italic> gene results in sterile immunity against the current epidemic Eurasia strain</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>e02017-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.02017-19</pub-id><pub-id pub-id-type="pmid">31969432</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00140"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopera-Madrid</surname><given-names>J.</given-names></name>
<name><surname>Medina-Magues</surname><given-names>L.G.</given-names></name>
<name><surname>Gladue</surname><given-names>D.P.</given-names></name>
<name><surname>Borca</surname><given-names>M.V.</given-names></name>
<name><surname>Osorio</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Optimization in the expression of ASFV proteins for the development of subunit vaccines using poxviruses as delivery vectors</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>23476</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-02949-x</pub-id><pub-id pub-id-type="pmid">34873256</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00140"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lokhandwala</surname><given-names>S.</given-names></name>
<name><surname>Waghela</surname><given-names>S.D.</given-names></name>
<name><surname>Bray</surname><given-names>J.</given-names></name>
<name><surname>Martin</surname><given-names>C.L.</given-names></name>
<name><surname>Sangewar</surname><given-names>N.</given-names></name>
<name><surname>Charendoff</surname><given-names>C.</given-names></name>
<name><surname>Shetti</surname><given-names>R.</given-names></name>
<name><surname>Ashley</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>C.H.</given-names></name>
<name><surname>Berghman</surname><given-names>L.R.</given-names></name>
<etal/>
</person-group><article-title>Induction of robust immune responses in swine by using a cocktail of adenovirus-vectored African swine fever virus antigens</article-title><source>Clin. Vaccine Immunol.</source><year>2016</year><volume>23</volume><fpage>888</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1128/CVI.00395-16</pub-id><pub-id pub-id-type="pmid">27628166</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00140"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chathuranga</surname><given-names>K.</given-names></name>
<name><surname>Lee</surname><given-names>J.S.</given-names></name>
</person-group><article-title>African swine fever virus (ASFV): Immunity and vaccine development</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>199</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11020199</pub-id><pub-id pub-id-type="pmid">36851077</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00140"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosowska</surname><given-names>A.</given-names></name>
<name><surname>Cadenas-Fernandez</surname><given-names>E.</given-names></name>
<name><surname>Barroso</surname><given-names>S.</given-names></name>
<name><surname>Sanchez-Vizcaino</surname><given-names>J.M.</given-names></name>
<name><surname>Barasona</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Distinct African swine fever virus shedding in wild boar infected with virulent and attenuated isolates</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>767</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8040767</pub-id><pub-id pub-id-type="pmid">33339147</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00140"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zajac</surname><given-names>M.D.</given-names></name>
<name><surname>Trujillo</surname><given-names>J.D.</given-names></name>
<name><surname>Yao</surname><given-names>J.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Sangewar</surname><given-names>N.</given-names></name>
<name><surname>Lokhandwala</surname><given-names>S.</given-names></name>
<name><surname>Sang</surname><given-names>H.</given-names></name>
<name><surname>Mallen</surname><given-names>K.</given-names></name>
<name><surname>McCall</surname><given-names>J.</given-names></name>
<name><surname>Burton</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Immunization of pigs with replication-incompetent adenovirus-vectored African swine fever virus multi-antigens induced humoral immune responses but no protection following contact challenge</article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>10</volume><elocation-id>1208275</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2023.1208275</pub-id><pub-id pub-id-type="pmid">37404778</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00140"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Ai</surname><given-names>Q.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Ou</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Tong</surname><given-names>T.</given-names></name>
<name><surname>Fan</surname><given-names>H.</given-names></name>
</person-group><article-title>Immune escape mechanism and vaccine research progress of African swine fever virus</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>344</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10030344</pub-id><pub-id pub-id-type="pmid">35334976</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00140"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bosch-Camos</surname><given-names>L.</given-names></name>
<name><surname>Lopez</surname><given-names>E.</given-names></name>
<name><surname>Rodriguez</surname><given-names>F.</given-names></name>
</person-group><article-title>African swine fever vaccines: A promising work still in progress</article-title><source>Porcine Health Manag.</source><year>2020</year><volume>6</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s40813-020-00154-2</pub-id><pub-id pub-id-type="pmid">32626597</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00140"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iyer</surname><given-names>L.M.</given-names></name>
<name><surname>Balaji</surname><given-names>S.</given-names></name>
<name><surname>Koonin</surname><given-names>E.V.</given-names></name>
<name><surname>Aravind</surname><given-names>L.</given-names></name>
</person-group><article-title>Evolutionary genomics of nucleo-cytoplasmic large DNA viruses</article-title><source>Virus Res.</source><year>2006</year><volume>117</volume><fpage>156</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2006.01.009</pub-id><pub-id pub-id-type="pmid">16494962</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00140"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Miao</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>H.</given-names></name>
</person-group><article-title>Structure and function of African swine fever virus proteins: Current understanding</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>1043129</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1043129</pub-id><pub-id pub-id-type="pmid">36846791</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00140"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Bai</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>An intracellular epitope of ASFV CD2v protein elicits humoral and cellular immune responses</article-title><source>Animals</source><year>2023</year><volume>13</volume><elocation-id>1967</elocation-id><pub-id pub-id-type="doi">10.3390/ani13121967</pub-id><pub-id pub-id-type="pmid">37370477</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00140"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Lv</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>Lai</surname><given-names>L.</given-names></name>
<name><surname>Duan</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>A new vaccination regimen using adenovirus-vectored vaccine confers effective protection against African swine fever virus in swine</article-title><source>Emerg. Microbes Infect.</source><year>2023</year><volume>12</volume><fpage>2233643</fpage><pub-id pub-id-type="doi">10.1080/22221751.2023.2233643</pub-id><pub-id pub-id-type="pmid">37401832</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00140"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Tian</surname><given-names>P.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhuang</surname><given-names>G.</given-names></name>
<name><surname>Jiang</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>A candidate nanoparticle vaccine comprised of multiple epitopes of the African swine fever virus elicits a robust immune response</article-title><source>J. Nanobiotechnol.</source><year>2023</year><volume>21</volume><elocation-id>424</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-023-02210-9</pub-id></element-citation></ref><ref id="B18-vetsci-12-00140"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jancovich</surname><given-names>J.K.</given-names></name>
<name><surname>Chapman</surname><given-names>D.</given-names></name>
<name><surname>Hansen</surname><given-names>D.T.</given-names></name>
<name><surname>Robida</surname><given-names>M.D.</given-names></name>
<name><surname>Loskutov</surname><given-names>A.</given-names></name>
<name><surname>Craciunescu</surname><given-names>F.</given-names></name>
<name><surname>Borovkov</surname><given-names>A.</given-names></name>
<name><surname>Kibler</surname><given-names>K.</given-names></name>
<name><surname>Goatley</surname><given-names>L.</given-names></name>
<name><surname>King</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Immunization of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e02219-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.02219-17</pub-id><pub-id pub-id-type="pmid">29386289</pub-id>
</element-citation></ref><ref id="B19-vetsci-12-00140"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dieye</surname><given-names>Y.</given-names></name>
<name><surname>Usai</surname><given-names>S.</given-names></name>
<name><surname>Clier</surname><given-names>F.</given-names></name>
<name><surname>Gruss</surname><given-names>A.</given-names></name>
<name><surname>Piard</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Design of a protein-targeting system for lactic acid bacteria</article-title><source>J. Bacteriol.</source><year>2001</year><volume>183</volume><fpage>4157</fpage><lpage>4166</lpage><pub-id pub-id-type="doi">10.1128/JB.183.14.4157-4166.2001</pub-id><pub-id pub-id-type="pmid">11418555</pub-id>
</element-citation></ref><ref id="B20-vetsci-12-00140"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cano-Garrido</surname><given-names>O.</given-names></name>
<name><surname>Rueda</surname><given-names>F.L.</given-names></name>
<name><surname>Sanchez-Garcia</surname><given-names>L.</given-names></name>
<name><surname>Ruiz-Avila</surname><given-names>L.</given-names></name>
<name><surname>Bosser</surname><given-names>R.</given-names></name>
<name><surname>Villaverde</surname><given-names>A.</given-names></name>
<name><surname>Garcia-Fruitos</surname><given-names>E.</given-names></name>
</person-group><article-title>Expanding the recombinant protein quality in <italic toggle="yes">Lactococcus lactis</italic></article-title><source>Microb. Cell Fact.</source><year>2014</year><volume>13</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s12934-014-0167-3</pub-id><pub-id pub-id-type="pmid">25471301</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00140"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>X.X.</given-names></name>
<name><surname>Li</surname><given-names>W.F.</given-names></name>
<name><surname>Ma</surname><given-names>G.X.</given-names></name>
<name><surname>Pan</surname><given-names>Y.J.</given-names></name>
</person-group><article-title>The nisin-controlled gene expression system: Construction, application and improvements</article-title><source>Biotechnol. Adv.</source><year>2006</year><volume>24</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2005.11.001</pub-id><pub-id pub-id-type="pmid">16380225</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00140"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Lv</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
</person-group><article-title>Immune responses to orally administered recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing multi-epitope proteins targeting M cells of foot-and-mouth disease virus</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2036</elocation-id><pub-id pub-id-type="doi">10.3390/v13102036</pub-id><pub-id pub-id-type="pmid">34696469</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00140"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fatehi</surname><given-names>Z.</given-names></name>
<name><surname>Doosti</surname><given-names>A.</given-names></name>
<name><surname>Jami</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Oral vaccination with novel <italic toggle="yes">Lactococcus lactis</italic> mucosal live vector-secreting <italic toggle="yes">Brucella</italic> lumazine synthase (BLS) protein induces humoral and cellular immune protection against <italic toggle="yes">Brucella abortus</italic></article-title><source>Arch. Microbiol.</source><year>2023</year><volume>205</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1007/s00203-023-03471-6</pub-id><pub-id pub-id-type="pmid">36939918</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00140"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Shi</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Bergmann</surname><given-names>S.M.</given-names></name>
<name><surname>Mo</surname><given-names>X.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing grass carp reovirus VP6 induces mucosal immunity against grass carp reovirus infection</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>914010</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.914010</pub-id><pub-id pub-id-type="pmid">35634331</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00140"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Jia</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>D.</given-names></name>
</person-group><article-title><italic toggle="yes">Eimeria tenella</italic>: IMP1 protein delivered by <italic toggle="yes">Lactococcus lactis</italic> induces immune responses against homologous challenge in chickens</article-title><source>Vet. Parasitol.</source><year>2021</year><volume>289</volume><fpage>109320</fpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2020.109320</pub-id><pub-id pub-id-type="pmid">33248421</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00140"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Feng</surname><given-names>T.</given-names></name>
<name><surname>Hou</surname><given-names>T.</given-names></name>
<name><surname>Zhu</surname><given-names>W.G.</given-names></name>
</person-group><article-title>Protocol to purify the histone deacetylase sirt6 and assess its activity <italic toggle="yes">in vitro</italic></article-title><source>Star. Protoc.</source><year>2023</year><volume>4</volume><fpage>102206</fpage><pub-id pub-id-type="doi">10.1016/j.xpro.2023.102206</pub-id><pub-id pub-id-type="pmid">36995934</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00140"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Qi</surname><given-names>L.</given-names></name>
<name><surname>Lv</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>P.</given-names></name>
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
</person-group><article-title>The immune response to a recombinant <italic toggle="yes">Lactococcus lactis</italic> oral vaccine against foot-and-mouth disease virus in mice</article-title><source>Biotechnol. Lett.</source><year>2020</year><volume>42</volume><fpage>1907</fpage><lpage>1917</lpage><pub-id pub-id-type="doi">10.1007/s10529-020-02900-6</pub-id><pub-id pub-id-type="pmid">32385744</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00140"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Gao</surname><given-names>T.</given-names></name>
<name><surname>Zhai</surname><given-names>H.</given-names></name>
<name><surname>Moon</surname><given-names>A.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Lan</surname><given-names>J.</given-names></name>
<name><surname>Zhong</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>A pool of bacterium-like particles displaying African swine fever virus antigens induces both humoral and cellular immune responses in pigs</article-title><source>Vaccines</source><year>2025</year><volume>13</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines13010005</pub-id><pub-id pub-id-type="pmid">39852784</pub-id>
</element-citation></ref><ref id="B29-vetsci-12-00140"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munoz-Perez</surname><given-names>C.</given-names></name>
<name><surname>Jurado</surname><given-names>C.</given-names></name>
<name><surname>Sanchez-Vizcaino</surname><given-names>J.M.</given-names></name>
</person-group><article-title>African swine fever vaccine: Turning a dream into reality</article-title><source>Transbound. Emerg. Dis.</source><year>2021</year><volume>68</volume><fpage>2657</fpage><lpage>2668</lpage><pub-id pub-id-type="doi">10.1111/tbed.14191</pub-id><pub-id pub-id-type="pmid">34137198</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00140"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Podgorski</surname><given-names>T.</given-names></name>
<name><surname>Pepin</surname><given-names>K.M.</given-names></name>
<name><surname>Radko</surname><given-names>A.</given-names></name>
<name><surname>Podbielska</surname><given-names>A.</given-names></name>
<name><surname>Lyjak</surname><given-names>M.</given-names></name>
<name><surname>Wozniakowski</surname><given-names>G.</given-names></name>
<name><surname>Borowik</surname><given-names>T.</given-names></name>
</person-group><article-title>How do genetic relatedness and spatial proximity shape African swine fever infections in wild boar?</article-title><source>Transbound. Emerg. Dis.</source><year>2022</year><volume>69</volume><fpage>2656</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1111/tbed.14418</pub-id><pub-id pub-id-type="pmid">34902218</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00140"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Qi</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Neutralizing-antibody-mediated protection of chickens against infectious bursal disease via one-time vaccination with inactivated recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing a fusion protein constructed from the RCK protein of <italic toggle="yes">Salmonella enterica</italic> and VP2 of infectious bursal disease virus</article-title><source>Microb. Cell Fact.</source><year>2019</year><volume>18</volume><fpage>21</fpage><pub-id pub-id-type="pmid">30704494</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00140"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>H.Q.</given-names></name>
<name><surname>Bos</surname><given-names>N.A.</given-names></name>
<name><surname>Cebra</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Timing, localization, and persistence of colonization by segmented filamentous bacteria in the neonatal mouse gut depend on immune status of mothers and pups</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>3611</fpage><lpage>3617</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.6.3611-3617.2001</pub-id><pub-id pub-id-type="pmid">11349021</pub-id>
</element-citation></ref><ref id="B33-vetsci-12-00140"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pietrzak</surname><given-names>B.</given-names></name>
<name><surname>Tomela</surname><given-names>K.</given-names></name>
<name><surname>Olejnik-Schmidt</surname><given-names>A.</given-names></name>
<name><surname>Mackiewicz</surname><given-names>A.</given-names></name>
<name><surname>Schmidt</surname><given-names>M.</given-names></name>
</person-group><article-title>Secretory IgA in intestinal mucosal secretions as an adaptive barrier against microbial cells</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>9254</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21239254</pub-id><pub-id pub-id-type="pmid">33291586</pub-id>
</element-citation></ref><ref id="B34-vetsci-12-00140"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>A.</given-names></name>
<name><surname>Weiner</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Induction of anergy or active suppression following oral tolerance is determined by antigen dosage</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>6688</fpage><lpage>6692</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.14.6688</pub-id><pub-id pub-id-type="pmid">8022835</pub-id>
</element-citation></ref><ref id="B35-vetsci-12-00140"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Kuchroo</surname><given-names>V.K.</given-names></name>
<name><surname>Inobe</surname><given-names>J.</given-names></name>
<name><surname>Hafler</surname><given-names>D.A.</given-names></name>
<name><surname>Weiner</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>1237</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1126/science.7520605</pub-id><pub-id pub-id-type="pmid">7520605</pub-id>
</element-citation></ref><ref id="B36-vetsci-12-00140"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagler-Anderson</surname><given-names>C.</given-names></name>
<name><surname>Bhan</surname><given-names>A.K.</given-names></name>
<name><surname>Podolsky</surname><given-names>D.K.</given-names></name>
<name><surname>Terhorst</surname><given-names>C.</given-names></name>
</person-group><article-title>Control freaks: Immune regulatory cells</article-title><source>Nat. Immunol.</source><year>2004</year><volume>5</volume><fpage>119</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/ni0204-119</pub-id><pub-id pub-id-type="pmid">14749778</pub-id>
</element-citation></ref><ref id="B37-vetsci-12-00140"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Churiso</surname><given-names>G.</given-names></name>
<name><surname>Husen</surname><given-names>G.</given-names></name>
<name><surname>Bulbula</surname><given-names>D.</given-names></name>
<name><surname>Abebe</surname><given-names>L.</given-names></name>
</person-group><article-title>Immunity cell responses to RSV and the role of antiviral inhibitors: A systematic review</article-title><source>Infect. Drug Resist.</source><year>2022</year><volume>15</volume><fpage>7413</fpage><lpage>7430</lpage><pub-id pub-id-type="doi">10.2147/IDR.S387479</pub-id><pub-id pub-id-type="pmid">36540102</pub-id>
</element-citation></ref><ref id="B38-vetsci-12-00140"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Yi</surname><given-names>S.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Niu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Hu</surname><given-names>G.</given-names></name>
</person-group><article-title>Construction of a recombinant <italic toggle="yes">Lactococcus lactis</italic> strain expressing a variant porcine epidemic diarrhea virus S1 gene and its immunogenicity analysis in mice</article-title><source>Viral. Immunol.</source><year>2019</year><volume>32</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1089/vim.2018.0108</pub-id><pub-id pub-id-type="pmid">30855219</pub-id>
</element-citation></ref><ref id="B39-vetsci-12-00140"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>A.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and protective efficacy of a recombinant <italic toggle="yes">Lactococcus lactis</italic> vaccine against HSV-1 infection</article-title><source>Microb. Cell Fact.</source><year>2024</year><volume>23</volume><fpage>244</fpage><pub-id pub-id-type="doi">10.1186/s12934-024-02517-8</pub-id><pub-id pub-id-type="pmid">39252072</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00140-f001"><label>Figure 1</label><caption><p>The construction of the recombinant plasmids and identification of soluble expressions of the eight ASFV antigens. (<bold>a</bold>) A schematic diagram of the recombinant plasmid expressing ASFV antigen. (<bold>b</bold>) Identification of the ASFV protein expressions of the r<italic toggle="yes">L. lactis</italic> strains by Western blotting. The r<italic toggle="yes">L. lactis</italic> strains were induced to express the proteins. Following ultrasonic disruption, the supernatant and precipitate were collected and subjected to SDS-PAGE electrophoresis to assess the expression status of the target proteins in these fractions.</p></caption><graphic xlink:href="vetsci-12-00140-g001" position="float"/></fig><fig position="float" id="vetsci-12-00140-f002"><label>Figure 2</label><caption><p>The growth characteristics and genetic stability of the r<italic toggle="yes">L. lactis</italic> strains. (<bold>a</bold>) The growth curve of the r<italic toggle="yes">L. lactis</italic> strains. Initially, the OD<sub>600nm</sub> values of the cultures were measured. Subsequently, the OD<sub>600nm</sub> values were recorded at hourly intervals until the bacterial stationary phase was reached. Utilizing these data points, the growth curves were constructed. (<bold>b</bold>) The detection of ASFV protein expressions in the 22nd-generation r<italic toggle="yes">L. lactis</italic> strains by Western blotting. The eight r<italic toggle="yes">L. lactis</italic> strains were subcultured daily, and upon reaching the 22nd generation, protein expressions were induced, and the supernatant and precipitate of the strain were collected using ultrasound to detect the presence of the target protein in these components.</p></caption><graphic xlink:href="vetsci-12-00140-g002" position="float"/></fig><fig position="float" id="vetsci-12-00140-f003"><label>Figure 3</label><caption><p>The mouse immunization schedule and sera IgG antibodies levels. (<bold>a</bold>) The mouse immunization schedule. The primary immunization, followed by oral gavage immunization on the subsequent day for a continuous period of 14 d. Two weeks later, a booster immunization was administered via oral gavage for three consecutive days. After another two weeks, a second booster immunization was given for three days. Each immunization was accompanied by a single intramuscular injection. (<bold>b</bold>) The level of specific IgG antibodies in the sera of the immunized mice. Each ASFV antigen protein was coated in 96-well microplates, and the serum specific IgG antibodies against different antigens in the immunized mice were detected by ELISA. The data were analyzed by a one-way analysis of variance. ns, <italic toggle="yes">p</italic> &#x02265; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vetsci-12-00140-g003" position="float"/></fig><fig position="float" id="vetsci-12-00140-f004"><label>Figure 4</label><caption><p>The sIgA antibodies in the feces of the immunized mice. Each ASFV antigen protein was coated in a 96-well microtiter plate, the levels of sIgA antibodies in the mice feces were detected by ELISA, and the statistical differences in the results were analyzed by a one-way analysis of variance. ns, <italic toggle="yes">p</italic> &#x02265; 0.05; *, <italic toggle="yes">p</italic> &#x0003c; 0.05; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vetsci-12-00140-g004" position="float"/></fig><fig position="float" id="vetsci-12-00140-f005"><label>Figure 5</label><caption><p>The levels of the Th1 cytokine subset (IFN-<italic toggle="yes">&#x003b3;</italic>, IL-2) and the Th2 cytokine subset (IL-4, IL-10) in the sera of immunized mice. ns, <italic toggle="yes">p</italic> &#x02265; 0.05; *, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="vetsci-12-00140-g005" position="float"/></fig><table-wrap position="float" id="vetsci-12-00140-t001"><object-id pub-id-type="pii">vetsci-12-00140-t001_Table 1</object-id><label>Table 1</label><caption><p>The primers used for constructing the recombinant plasmids.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequences (5&#x02032;-3&#x02032;)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">F317L-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGTTGAAACACAAATGGAT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H171R-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGTTGTTTATGATCTTCTT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">D117L-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGATACAGAAACTTCACCT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">E120R-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGCTGATTTTAATTCACCA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">B602L-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGCTGAATTTAATATT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CD2v-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGATTATTCTTATTTTTCTT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p54-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGATTCAGAATTT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p72-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTCACCATGGCTTCAGGTGGA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Common-R</td><td align="left" valign="middle" rowspan="1" colspan="1">AAGCTTGAGCTCTCACTTCTCGAACTGGGG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">pNZ8149-F</td><td align="left" valign="middle" rowspan="1" colspan="1">GGTACCACTAGTTCTAGAGAGCTC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pNZ8149-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCATGCCTGCAGTACCCATGGTGA</td></tr></tbody></table><table-wrap-foot><fn><p>Common-R represents the same reverse primer for all the target genes.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-12-00140-t002"><object-id pub-id-type="pii">vetsci-12-00140-t002_Table 2</object-id><label>Table 2</label><caption><p>The immunization doses and routes of r<italic toggle="yes">L. lactis</italic> in mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amount</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunogens</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunizing dose</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunization route</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">A</td><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="left" valign="middle" rowspan="1" colspan="1">r<italic toggle="yes">L. lactis</italic>-mix</td><td align="left" valign="middle" rowspan="1" colspan="1">8 &#x000d7; 10<sup>9</sup> CFU</td><td align="left" valign="middle" rowspan="1" colspan="1">oral gavage</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">B</td><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">L. lactis</italic>-pNZ8149 </td><td align="left" valign="middle" rowspan="1" colspan="1">8 &#x000d7; 10<sup>9</sup> CFU</td><td align="left" valign="middle" rowspan="1" colspan="1">oral gavage</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">C</td><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="left" valign="middle" rowspan="1" colspan="1">PBS</td><td align="left" valign="middle" rowspan="1" colspan="1">200 &#x003bc;L</td><td align="left" valign="middle" rowspan="1" colspan="1">oral gavage</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">r<italic toggle="yes">L. lactis</italic>-mix</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000d7; 10<sup>9</sup> CFU</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">intramuscular injection</td></tr></tbody></table></table-wrap></floats-group></article>